Iradimed's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Iradimed's ROA in the third quarter of 2026?
Iradimed Corporation achieved a return on average assets (ROA) of 20.64 % in its third quarter of 2026, this is above IRMD's average return on assets of 13.46%.
Iradimed Corporation assets over the 12 months ending in its third quarter of 2026 are valued at $116 million

ROA has improved compared to 20.26% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 45 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 208, from total ROA ranking in the second quarter of 2026 at 237.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	8.61 %	11.5 %	14.65 %	11.97 %	22.23 %
Y / Y Net Income Change	16.66 %	-9.63 %	24.12 %	25.16 %	10.44 %
Net Income (TTM) in million	24	23	24	22	21
Return On Assets (TTM)	20.64 %	20.26 %	21.32 %	20.99 %	20.34 %
IRMD's Total Ranking	# 208	# 237	# 237	# 226	# 224
Total Assets (TTM) in million	124	118	114	109	114
Seq. Total Assets Change	5.15 %	3.02 %	5.16 %	-4.65 %	7.95 %
Seq. Net Income Change	24.68 %	-10.31 %	-9.69 %	15.52 %	-3.42 %

IRMD's 5 Years Annual ROA >> Back to IRMD Management Effectiveness >> Compare IRMD ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 8
Sector	# 46
Overall	# 208

Return On Assets Statistics
High	Average	Low
26.6 %	13.46 %	-19.55 %
(Jun 30 2016)		(Mar 31 2015)

Financial Statements
Iradimed's Assets	$ 124 million	IRMD's Balance sheet
Iradimed's Income	$ 7 million	Quarterly IRMD's Income Statement
IRMD's Income by Division		See IRMD's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	11.97 %	0.55 %	12.99 %	3.74 %	15.99 %
Total Assets in million	109	97	97	86	82
Y / Y Net Income Change	16.88 %	11.87 %	34.02 %	37.56 %	581.19 %
Net Income in million	22	19	17	13	9
Annual Return On Assets	20.67 %	19.8 %	17.79 %	15 %	11.31 %

IRMD's 5 Years Annual ROA >> Back to IRMD Management Effectiveness >> Compare IRMD ROA to its Competitors

Comment on IRMD's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 20.67 % compared to prior year, due to annual net income growth of 16.88 % to $22.48 million, while value of Iradimed's overall assets grew just by 11.97 % to $108.78 million, compared to $108.78 a year before.

More Return On Assets Ratios
IRMD's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IRMD's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IRMD's Competitors
Subscribers only: Roa for Iradimed's Suppliers
Subscribers only: Return On Assets for IRMD's Customers

You may also want to know
IRMD's Roi	IRMD's Inventory Turnover Ratio	IRMD's Growth Rates	IRMD's Dividend Comparisons
	IRMD's Profitability Ratios	IRMD's Asset Turnover Ratio	IRMD's Dividend Growth
IRMD's Roe	IRMD's Valuation Ratios	IRMD's Financial Strength Ratios	IRMD's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %

Date modified: 2026-10-31T09:56:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.